1151 related articles for article (PubMed ID: 30951251)
1. Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study.
Sparks JA; He X; Huang J; Fletcher EA; Zaccardelli A; Friedlander HM; Gill RR; Hatabu H; Nishino M; Murphy DJ; Iannaccone CK; Mahmoud TG; Frits ML; Lu B; Rosas IO; Dellaripa PF; Weinblatt ME; Karlson EW; Shadick NA; Doyle TJ
Arthritis Rheumatol; 2019 Sep; 71(9):1472-1482. PubMed ID: 30951251
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease.
Li L; Liu R; Zhang Y; Zhou J; Li Y; Xu Y; Gao S; Zheng Y
Clin Rheumatol; 2020 May; 39(5):1457-1470. PubMed ID: 31858341
[TBL] [Abstract][Full Text] [Related]
3. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.
Rojas-Serrano J; Herrera-Bringas D; Pérez-Román DI; Pérez-Dorame R; Mateos-Toledo H; Mejía M
Clin Rheumatol; 2017 Jul; 36(7):1493-1500. PubMed ID: 28585060
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients.
Sparks JA; Jin Y; Cho SK; Vine S; Desai R; Doyle TJ; Kim SC
Rheumatology (Oxford); 2021 Aug; 60(8):3689-3698. PubMed ID: 33462611
[TBL] [Abstract][Full Text] [Related]
5. The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
Wang HF; Wang YY; Li ZY; He PJ; Liu S; Li QS
Ann Med; 2024 Dec; 56(1):2332406. PubMed ID: 38547537
[TBL] [Abstract][Full Text] [Related]
6. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.
Kiely P; Busby AD; Nikiphorou E; Sullivan K; Walsh DA; Creamer P; Dixey J; Young A
BMJ Open; 2019 May; 9(5):e028466. PubMed ID: 31061059
[TBL] [Abstract][Full Text] [Related]
7. Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
Xie M; Zhu C; Ye Y
BMC Pulm Med; 2023 Jul; 23(1):255. PubMed ID: 37434169
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of rheumatoid arthritis patients with interstitial lung disease: baseline data of a single-center prospective cohort.
Kim H; Cho SK; Song YJ; Kang J; Jeong SA; Kim HW; Choi CB; Kim TH; Jun JB; Bae SC; Yoo DH; Lee H; Park DW; Sohn JW; Yoon HJ; Hong SJ; Yoo SJ; Choi YW; Lee Y; Kim SH; Sung YK
Arthritis Res Ther; 2023 Mar; 25(1):43. PubMed ID: 36932433
[TBL] [Abstract][Full Text] [Related]
9. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
Curtis JR; Sarsour K; Napalkov P; Costa LA; Schulman KL
Arthritis Res Ther; 2015 Nov; 17():319. PubMed ID: 26555431
[TBL] [Abstract][Full Text] [Related]
10. Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers.
Doyle TJ; Patel AS; Hatabu H; Nishino M; Wu G; Osorio JC; Golzarri MF; Traslosheros A; Chu SG; Frits ML; Iannaccone CK; Koontz D; Fuhrman C; Weinblatt ME; El-Chemaly SY; Washko GR; Hunninghake GM; Choi AM; Dellaripa PF; Oddis CV; Shadick NA; Ascherman DP; Rosas IO
Am J Respir Crit Care Med; 2015 Jun; 191(12):1403-12. PubMed ID: 25822095
[TBL] [Abstract][Full Text] [Related]
11. Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis.
Restrepo JF; del Rincón I; Battafarano DF; Haas RW; Doria M; Escalante A
Clin Rheumatol; 2015 Sep; 34(9):1529-36. PubMed ID: 26255186
[TBL] [Abstract][Full Text] [Related]
12. Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease.
Kronzer VL; Huang W; Dellaripa PF; Huang S; Feathers V; Lu B; Iannaccone CK; Gill RR; Hatabu H; Nishino M; Crowson CS; Davis JM; Weinblatt ME; Shadick NA; Doyle TJ; Sparks JA
J Rheumatol; 2021 May; 48(5):656-663. PubMed ID: 33191286
[TBL] [Abstract][Full Text] [Related]
13. Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease in Women with Rheumatoid Arthritis.
Rocha-Muñoz AD; Ponce-Guarneros M; Gamez-Nava JI; Olivas-Flores EM; Mejía M; Juárez-Contreras P; Martínez-García EA; Corona-Sánchez EG; Rodríguez-Hernández TM; Vázquez-del Mercado M; Salazar-Páramo M; Nava-Zavala AH; Cardona-Muñoz EG; Celis A; González-Lopez L
J Immunol Res; 2015; 2015():151626. PubMed ID: 26090479
[TBL] [Abstract][Full Text] [Related]
14. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.
Akiyama M; Kaneko Y; Yamaoka K; Kondo H; Takeuchi T
Rheumatol Int; 2016 Jun; 36(6):881-9. PubMed ID: 27072347
[TBL] [Abstract][Full Text] [Related]
15. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept.
Mochizuki T; Ikari K; Yano K; Sato M; Okazaki K
Mod Rheumatol; 2019 May; 29(3):413-417. PubMed ID: 29798700
[TBL] [Abstract][Full Text] [Related]
16. Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival.
England BR; Sayles H; Michaud K; Thiele GM; Poole JA; Caplan L; Sauer BC; Cannon GW; Reimold A; Kerr GS; Baker JF; Mikuls TR
Clin Rheumatol; 2018 Nov; 37(11):2907-2915. PubMed ID: 30280369
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory Biomarkers in the Diagnosis and Prognosis of Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Mena-Vázquez N; Godoy-Navarrete FJ; Lisbona-Montañez JM; Redondo-Rodriguez R; Manrique-Arija S; Rioja J; Mucientes A; Ruiz-Limón P; Garcia-Studer A; Ortiz-Márquez F; Oliver-Martos B; Cano-García L; Fernández-Nebro A
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047772
[TBL] [Abstract][Full Text] [Related]
18. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
[TBL] [Abstract][Full Text] [Related]
19. Analysis of risk factors of mortality in rheumatoid arthritis patients with interstitial lung disease: a nationwide, population-based cohort study in Taiwan.
Ng KH; Chen DY; Lin CH; Chao WC; Chen HH
RMD Open; 2022 Aug; 8(2):. PubMed ID: 35995491
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
Baker MC; Liu Y; Lu R; Lin J; Melehani J; Robinson WH
JAMA Netw Open; 2023 Mar; 6(3):e233640. PubMed ID: 36939701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
